Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 7/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | USP14 | P54578 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.35 |
| ▸ | ACACB | O00763 | 5/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PTGES | O14684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10051929 | 0.92 | USP14 (0.39) | MEN1KMT2AUSP14PTGDR2ACACB | |
| SCHEMBL504146 | 0.84 | USP14 (0.41) | MEN1KMT2AUSP14KDM4E | |
| SCHEMBL503508 | 0.83 | MEN1 (0.41) | MEN1KMT2AUSP14KDM4E | |
| SCHEMBL333231 | 0.83 | MEN1 (0.48) | MEN1KMT2AUSP14PTGDR2KDM4E | |
| SCHEMBL503872 | 0.82 | USP14 (0.48) | MEN1KMT2AUSP14PTGDR2KDM4E | |
| SCHEMBL334235 | 0.82 | BCL2 (0.42) | MEN1KMT2AUSP14ACACBKDM4E | |
| SCHEMBL10051932 | 0.82 | MEN1 (0.36) | MEN1KMT2AUSP14PTGDR2KDM4E | |
| SCHEMBL334350 | 0.81 | PTGES (0.52) | MEN1KMT2AKDM4EPTGES | |
| SCHEMBL334349 | 0.80 | PPARG (0.44) | MEN1KMT2APTGDR2PTGES | |
| SCHEMBL504356 | 0.80 | PPARG (0.42) | MEN1KMT2AUSP14KDM4EPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029016-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SW) | 2012-02-02 | — | — | US | disclosed |
| US-20120029016-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SW) | 2012-02-02 | — | — | US | disclosed |
| US-20120029016-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SW) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029016-A1 | Indoles Useful in the Treatment of Inflammation | LTC4S, LTB4R2, LTB4R | IDH1 1420/4885MEN1 2934/4885KMT2A 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.